NCT00889057CompletedPhase 2
Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Italian Sarcoma Group
- Enrollment
- 35
- Locations
- 4
- Primary Endpoint
- Tumor assessment through radiologic evaluation.
Study Overview
Brief Summary
Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 15 Years to 75 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •histologically documented and not surgically resectable or metastatic high-grade osteosarcoma which progressed after first or second line treatments for relapsing disease.
- •measurable disease as defined by having at least one lesion that can be accurately measured by means of CT or MRI.
- •ECOG PS of 0, 1 and an estimated life expectancy of at least 3 months. ECOG P.S. 2 is acceptable provided that it depends solely on orthopedic problems
- •Age ≥15 years.
- •Adequate bone marrow, liver and renal function
- •Written informed consent
Exclusion Criteria
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
- •Coexisting malignancies, except for basal or epithelial cell carcinoma of the skin or other solid tumors curatively treated with no evidence of disease for ≥3 years.
- •History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •History of HIV infection or chronic hepatitis B or C.
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
- •Patients with seizure disorders requiring medication (such as steroids or anti-epileptics)
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
- •Patients unable to swallow oral medications
Arms & Interventions
sorafenib
Experimental
Intervention: sorafenib (Drug)
Outcomes
Primary Outcomes
Tumor assessment through radiologic evaluation.
Time Frame: every 8 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Prof. Massimo Aglietta
Professor
Italian Sarcoma Group
Study Sites (4)
Loading locations...
Similar Trials
Unknown
Phase 2
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin TreatmentColorectal NeoplasmsNCT00839111Fudan University43
Completed
Phase 2
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsThyroid CarcinomaNCT02114658Bayer18
Terminated
Phase 2
Sorafenib in Resected Non-small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungNCT00532025Johannes Gutenberg University Mainz134
Active, not recruiting
Phase 1
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
Active, not recruiting
Not Applicable
Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older - Sorafenib in Child Pugh Score B patientshepatocellular carcinoma and Child Pugh score BMedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-008232-87-DECharite Universitätsmedizin Berlin- Campus Virchow-Klinikum